Replay available

Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call

Fortress Biotech, Inc. (NASDAQ: FBIO) Q3 2025 earnings conference call, held 2025-11-12. Replay captured from the company's public earnings webcast.

Wed, November 12, 2025 at 4:30 PMendedReplay
Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Jacqueline Jaffe

Senior Director of Corporate Operations

Claude Morali

Co-Founder, President, and Chief Executive Officer

Thomas Flatton

Analyst at Lake Street Capital Markets

Scott Henry

Analyst at AGP

Brandon Foltz

Analyst at H.C. Wainwright

Ramzi Aloush

Chief Operating Officer and General Counsel

Joseph Benesch

Chief Financial Officer

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to Journey Medical's third quarter 2025 financial results and corporate update conference call. At this time, all participants will be in a listen-only mode. Should you need assistance, please signal conference specialist by pressing the star key followed by zero. Participants of this call are advised that the audio of this call is being broadcast live over the internet and is also being recorded for playback purposes. A webcast replay of this call will be available approximately one hour after the call for approximately 30 days. I would now like to turn the call over to Ms. Jacqueline Jaffe, the company's senior director of corporate operations. Please go ahead, Jacqueline. Good afternoon, and thank you for participating in today's conference call. Joining me from Journey Medical's leadership team are Claude Morali, co-founder, president, and chief executive officer, and Joseph Benesch, chief financial officer. Joining for the Q&A portion of the call will be Ramzi Aloush, Chief Operating Officer and General Counsel. During this call, management will be making forward-looking statements, including statements that address, among other things, Journey Medical's expectations for future performance, operational results, financial condition, and the receipt of regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors described in Journey Medical's most recently filed periodic reports on Form 10-K and Form 10-Q. The Form 8-K files with the SEC today and the company's press release that accompanies this call, particularly the cautio...

More from Fortress Biotech, Inc.